Indoleamine-2,3-dioxygenase

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

Indoleamine-2,3-dioxygenase or indolamine-2,3-dioxygenase or IDO is an enzyme involved in the human body's metabolism of the essential amino acid tryptophan.[1][2]

The IDO enzyme degrades (converts) tryptophan into kynurenine, and this process is strongly linked to the IDO1 and IDO2 genes.[1][3]

Notable studies and publications[edit | edit source]

  • 2019, The IDO Metabolic Trap Hypothesis for the Etiology of ME/CFS[2] (Full text)

Learn more[edit | edit source]

  • 2020, IDO and Kynurenine Metabolites in Peripheral and CNS Disorders (Full text)
  • 2018, Indoleamine 2, 3-dioxygenase regulation of immune response (Review)[4] (Full text)

See also[edit | edit source]

References[edit | edit source]

  1. 1.0 1.1 Bilir, Cemil; Sarisozen, Can (July 1, 2017). "Indoleamine 2,3-dioxygenase (IDO): Only an enzyme or a checkpoint controller?". Journal of Oncological Sciences. 3 (2): 52–56. doi:10.1016/j.jons.2017.04.001. ISSN 2452-3364.
  2. 2.0 2.1 Phair, RobertD.; Davis, Ronald W.; Kashi, Alex A. (2019). "The IDO Metabolic Trap Hypothesis for the Etiology of ME/CFS". Diagnostics. 9 (3): 82. doi:10.3390/diagnostics9030082.
  3. National Center for Biotechnology Information (March 22, 2020). "IDO1 indoleamine 2,3-dioxygenase 1 [Homo sapiens (human)] - Gene - NCBI". ncbi.nlm.nih.gov. Retrieved May 1, 2020.
  4. https://doi.org/10.3892/mmr.2018.8537